New Investigational Medication for Mild Alzheimer’s Disease

A 5 month study comparing 3 different doses of BMS-241027 vs. placebo.  To assess safety, tolerability, and the effects of 9 weekly IV infusions on CSF Tau, MRI functional connectivity, cognitive performance, and pharmacokinetics.

  • Ages 50-90
  • MMSE score of 20-26
  • Must be on a stable dose (at least 3 months) of cholinesterase inhibitors or NMDA antagonists